Evaluation of Antileishmanial Effect of Hydroalcoholic Extract of Ganoderma Leucidum on Leishmania Major in Vitro

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

4 PhD Student, Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Leishmania major is the causative agent of cutaneous leishmaniasis in Iran. Because of the side effects of current drugs and the emergence of drug resistance in some areas, researchers have been seeking for more effective and non-complicated compounds, especially herbal medicines and natural compounds, for the treatment of leishmaniasis. The aim of this study was to evaluate the antileishmanial effect of hydroalcoholic extract of Ganoderma leucidum on Leishmania major compared to commonly used drugs.Methods: Iranian Leishmania major parasite species (MRHO/IR/75/ER) was cultured in Novy-Mac Neal-Nicolle (NNN) and Roswell Park Memorial Institute-1640 (RPMI)-enriched media, and in the metacyclic phase transferred to a 96-well plate at the time of preparation of the hydroalcoholic extracts. Then, concentrations of 10, 50, 100, 150, and 200 µg/ml were used at 24, 48, and 72 hours. The amount of live promastigotes was assessed by using a hemocytometer and MTT colorimetric assay. Data were analyzed using Kolmogorov-Simonov, ANOVA, and repeated measures ANOVA tests, and P < 0.05 was considered as a meaningful level.Findings: The hydroalcoholic extract of this mushroom at high concentrations (150 and 200 µg/ml) inhibited the growth of the parasite significantly, and had a direct correlation with the increase of time (P < 0.001). Moreover, in the MTT method, it was a significant difference in the mean of optical absorption of different extract concentrations at 24, 48, and 72 hours (P < 0.001).Conclusion: The observed antileishmanial effect of Ganoderma leucidum extract on the number and growth of live promastigotes at high concentrations can be resulted due to its compounds such as tannins, flavonoids, triterophenides, and polysaccharides. It requires further research on the purification of its compounds and work on the animal model of Leishmaniasis.

Keywords

References

  1. Scorza BM, Carvalho EM, Wilson ME. Cutaneous Manifestations of human and murine leishmaniasis. Int J Mol Sci 2017; 18(6): 1296.
  2. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7(5): e35671.
  3. Shirzadi MR, Esfahania SB, Mohebalia M, Ershadia MR, Gharachorlo F, Razavia MR, et al. Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012. East Mediterr Health J 2015; 21(10): 736-42.
  4. Arana B, Rizzo N, Diaz A. Chemotherapy of cutaneous leishmaniasis: A review. Med Microbiol Immunol 2001; 190(1-2): 93-5.
  5. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One 2017; 12(9): e0184777.
  6. Rocha LG, Almeida JR, Macedo RO, Barbosa-Filho JM. A review of natural products with antileishmanial activity. Phytomedicine 2005; 12(6-7): 514-35.
  7. Kolodziej H, Kiderlen AF. Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry 2005; 66(17): 2056-71.
  8. Nilforoushzadeh MA, Shirani-Bidabadi L, Zolfaghari-Baghbaderani A, Saberi S, Siadat AH, Mahmoudi M. Comparison of Thymus vulgaris (Thyme), Achillea millefolium (Yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb/c mice. J Vector Borne Dis 2008; 45(4): 301-6.
  9. Kermani EK, Sajjadi SE, Hejazi SH, Arjmand R, Saberi S, Eskandarian AA. Anti-leishmania activity of osthole. Pharmacognosy Res 2016; 8(Suppl 1): S1-S4.
  10. Gao JJ, Min BS, Ahn EM, Nakamura N, Lee HK, Hattori M. New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem Pharm Bull (Tokyo) 2002; 50(6): 837-40.
  11. Smith JE, Rowan NJ, Sullivan R. Medicinal mushrooms: Their therapeutic properties and current medical usage with special emphasis on cancer treatments. Glasgow, UK: University of Strathclyde and Cancer Research, UK: 2002.
  12. McKenna DJ, Jones K, Hughes K, Humphrey S. Botanical medicines: The desk reference for major herbal supplements. 2nd ed. New York, NY: Haworth Herbal Press; 2002. p. 825-55.
  13. Kim HW, Kim BK. Biomedicinal triterperoids of Ganoderma lucidum (Curt.:Fr.) P. Karst. (Aphyllophoromycetideae). Int J Med Mushrooms 1999; 1: 121-38.
  14. Badalyan SM, Gharibyan NG, Kocharyan AE. Perspectives in the Usage of Bioactive Substances of Medicinal Mushrooms in Pharmaceutical and Cosmetic Industries. Int J Med Mushrooms 2007; 9(3-4): 275-6.
  15. Varshosaz J, Arbabi B, Pestehchian N, Saberi S, Delavari M. Chitosan-titanium dioxide-glucantime nanoassemblies effects on promastigote and amastigote of Leishmania major. Int J Biol Macromol 2018; 107(Pt A): 212-21.
  16. Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M. Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int 2005; 54(2): 119-22.
  17. Fumarola L, Spinelli R, Brandonisio O. In vitro assays for evaluation of drug activity against Leishmania spp. Res Microbiol 2004; 155(4): 224-30.
  18. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27(5): 305-18.
  19. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV. Recent advances in leishmaniasis treatment. Int J Infect Dis 2011; 15(8): e525-e532.
  20. Saberi S, Arjmand R, Soleimanifard S, Khamesipour A, Hosseini SM, Salehi M, et al. In vivo/In vitro immune responses to L. major isolates from patients with no clinical response to Glucantime. Adv Biomed Res 2016; 5: 126.
  21. Rocha LG, Almeida JR, Macedo RO, Barbosa-Filho JM. A review of natural products with antileishmanial activity. Phytomedicine 2005; 12(6-7): 514-35.
  22. Lindequist U, Niedermeyer TH, Julich WD. The pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2005; 2(3): 285-99.
  23. Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A, et al. Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). An immunomodulator from a fungus, Ganoderma lucidium, having similarity to immunoglobulin variable regions. J Biol Chem 1989; 264(28): 16372-7.
  24. Castillo D, Arevalo J, Herrera F, Ruiz C, Rojas R, Rengifo E, et al. Spirolactone iridoids might be responsible for the antileishmanial activity of a Peruvian traditional remedy made with Himatanthus sucuuba (Apocynaceae). J Ethnopharmacol 2007; 112(2): 410-4.
  25. Zhang HN, Lin ZB. Hypoglycemic effect of Ganoderma lucidum polysaccharides. Acta Pharmacol Sin 2004; 25(2): 191-5.
  26. Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Benzie IFF, Wachtel-Galor S, editors. Source Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton, FL: CRC Press/Taylor and Francis; 2011.
  27. Sivaprakasam E, Balakumar R, Kavitha D. Evaluation Of Antibacterial And Antifungal Activity Of Ganoderma Lucidum (Curtis) P. Karst Fruit Bodies Extracts. World Journal of Science and Technology 2011; 1(6): 8-11.
  28. Wadt N, Okamoto M, Hi E, Bach E. Chemical, toxicological, anti-inflammatory and antimicrobial evaluation of ganoderma lucidum extracts. Emir J Food Agric 201; 27(7): 577-84.
Journal of Isfahan Medical School
Volume 36, Issue 511 - Serial Number 511
November and December 2019
Pages 1628-1634

Files

History

  • Receive Date: 08 October 2018
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics